Familial hypercholesterolaemia is commonly caused by mutations in the low density lipoprotein receptor (LDLR) gene and more than 300 different mutations have been described worldwide. Some mutations occur at relatively higher frequency in certain populations, reflecting both chance and demography, most evident in founder populations. As part of a study of kindreds of 78 probands from Southampton and south west Hampshire, we identified the same mutation (R329X) in 9/78 (11.5%) probands. In all (100%) of these probands, length allele 259nt of the 17 allele microsatellite D19S394, sited approximately 250 kilobases telomeric and 5' to the LDLR gene, was observed, although in the general population this allele has a prevalence of only 16.1%. A simple diagnostic assay for R329X was constructed in conjunction with more detailed family studies. Both the R329X and linked D19S394 allele also cosegregated with the FH phenotype within each kindred. Although R329X involves a CpG site, it is highly likely that the families are identical by descent for R329X, we surmise with a common ancestor within 500 to 1000 years, although the mutation is not restricted to this geographical area. This relationship illustrates that the linkage disequilibrium of gene LDLR with marker D19S394 will enable rapid recognition using D19S394 genotype of possible common FH mutation(s) within a cohort of FH patients from a particular locality or ethnic group.
mutations occur at relatively higher frequency in certain populations, reflecting both chance and demography, most evident in founder populations. As part of a study of kindreds of 78 probands from Southampton and south west Hampshire, we identified the same mutation (R329X) in 9/78 (11.5%) probands. In all (100%) of these probands, length allele 259nt of the 17 allele microsatellite D19S394, sited approximately 250 kilobases telomeric and 5' to the LDLR gene, was observed, although in the general population this allele has a prevalence of only 16.1%. A simple diagnostic assay for R329X was constructed in conjunction with more detailed family studies. Both the R329X and linked D19S394 allele also cosegregated with the FH phenotype within each kindred. Although R329X involves a CpG site, it is highly likely that the families are identical by descent for R329X, we surmise with a common ancestor within 500 to 1000 years, although the mutation is not restricted to this geographical area. This relationship illustrates that the linkage disequilibrium of gene LDLR with marker D19S394 will enable rapid recognition using D19S394 genotype of possible common FH mutation(s) within a cohort of FH patients from a particular locality or ethnic group. Familial hypercholesterolaemia (FH) is a common inherited disease showing an autosomal dominant pattern of inheritance defined as being attributable to molecular defects in the LDL receptor.' It is characterised clinically by a rise in the concentration of low density lipoprotein (LDL) cholesterol in blood, tendon xanthomata, and an increased risk of myocardial infarction. Based on the estimated population frequency of carriers of 1/500, there are more than 110 000 FH heterozygotes in the UK, of whom probably fewer than 30-50% are even known to 14 ."-"3 However, there may be increased prevalence of some mutations in some regions. So far in England, only one such mutation has been identified, which accounts for approximately 10% of FH in the Manchester area," and which is widely distributed in the UK with a more typical prevalence of 1-2% among FH patients.5 However, many of the reported studies have been on patients from London clinics, which have a highly heterogeneous mix of patients. The objectives of this study were to identify any mutation which might be common in the south of England and to examine highly polymorphic microsatellite D19S394 on chromosome 19p,4 currently under study as a marker for cosegregation studies of FH families (L Haddad, I Day, in preparation), for linkage disequilibrium with any common mutation found. DNA from probands and from some relatives was purified as described previously from standard 5 ml potassium-EDTA venous blood.'5 For some relatives, DNA was purified as described previously'6 from mouthwash samples obtained by postal return. Mouthwash samples were obtained in 10 ml aliquots after written consent and telephone interview. Patients were supplied with a 20 ml sterilin tube containing 10 ml of sterile isotonic saline, which they were instructed to draw into their mouth and swill for 30 seconds before spitting back into the tube. Sterilin tubes were supplied and returned in breakproof packaging which fits most letter boxes. Mouthwash samples were found to yield very good PCR template DNA even after one to three days transit at ambient temperature or storage at -20°C before DNA extraction or both.
SSCP ANALYSIS AND SEQUENCING
SSCP and sequencing were undertaken as described previously for a study of LDLR gene exon 3,'3 except that primers for LDLR gene exon 74 were used in the present study. Primers were from Genosys, Cambridge, UK. Optimal PCR conditions were: a denaturation step for one minute at 94°C, followed by an annealing temperature of 58°C for one minute and an extension of 720C for two minutes for the first five cycles, followed by 30 
RESTRICTION SITE ASSAYS FOR R329X
BsrI digests the sequence CCAGT and therefore enables a specific assay for mutation R329X, in which the normal sequence CCAGC is mutated to CCAGT. Consistent with the manufacturer's recommendations (New England Biolabs, personal communication), it was found essential to purify the PCR product from the constituents of the PCR mix before digestion. Using PCR primers as used for SSCP, normal sequence yields a 169 base pair product, but this is cleaved to 128 and 41 base pair products only if the R329X mutation is present.
The use of two primers sited directly adjacent to the CpG sequence of codon 329 (TpG for R329X), in which the 3' bases of both primers is T, leads to PCR induction of a TaqI site in the normal sequence. Any mutation at the CpG site, including R329X, will ablate the TaqI site produced, yielding a sensitive but not necessarily specific assay for R329X. This approach has been developed into a general system for analysis of any CpG site,"' combining up to two 3' mismatched PCR primers, very short PCR (that is, oligonucleotides plus intervening CpG), TaqI digestion, and polyacrylamide microplate array diagonal gel electrophoresis (MADGE) analysis.'8 Among other
CpG mutations and forcing of other four base restriction sites containing CpG, the TaqI assay for R329X is considered in detail in reference 17.
Results

PROBANDS POSSESSING R329X MUTATION
Probands identified were a subset of those described previously and fulfilled standard criteria for probable or definite familial hypercholesterolaemia. Probands' ages ranged from 17 to 46 years and untreated cholesterol levels were from 9.5 to 12.3 mmol/l. Two probands had xanthomata, one knew of xanthomata in an uncle, two had distinctive corneal arcus, and one had distinctive xanthelasmata. In every case the cholesterol level was approximately twice the reference value for age ( (fig 2) , and has consistently shown heterozygosity above 0.9 in all populations studied (fig 2) (L Haddad, I Day, in preparation).
Discussion
The identification of LDLR mutation R329X enables direct diagnostic testing for approximately 10% of FH kindreds in the south of England; prevalence elsewhere is unknown. However, it has previously been reported in a single Norwegian family from Fossum,'9 although the affected grandparent from this isolated family originated from an area north of London, UK (T Leren, personal communication). An initial survey of one London clinic showed 2/50 families positive for R329X; one family is from Wales (J Betteridge, personal communication). R329X has also been observed in Holland,"9 although the earlier ancestry is not yet known. It should be noted that the apparent FH ancestor of one family examined in this study originated in York. R329X occurs at a CpG site and might represent a recurrent mutation at a CpG "hotspot"." However, there is strong evidence (see below) that R329X is identical by descent in all of the patients studied here. These data, taken together, suggest that R329X from a remote common ancestor may be relatively widespread in the UK and possibly in Europe, but probably with local expansion in numbers in the south of England. As discussed previously,'9 R329X is a null mutation; the characteristics of the families studied here are consistent in that all display clearcut FH.
Several approaches to construction of a simple direct genetic assay for R329X were examined. Sequencing is definitive but laborious. SSCP is somewhat simpler, but still introduces a complex stage of post-PCR analysis. Additionally, the SSCP band pattern of R329X cannot be considered definitive, although from a range of different mutations identified in exon 7 of the LDLR gene5 we have not observed any other mutation with an identical A SSCP profile. The R329X mutation creates a BsrI site (5'-CCAGT), opening the possibility of a restriction site assay completely specific to R329X. However, BsrI, a thermophilic restriction enzyme, is well known to have stringent requirements for activity, and it proved necessary to purify PCR product (and concentrate it) to enable sufficient digestion and product detectable using ethidium bromide. Although fully specific, this procedure proved no more convenient than SSCP and was therefore used solely for verification of probands. Use of a PCR induced restriction site, such that an artifically created TaqI site is present in the PCR product from normal alleles, but is eliminated by the R329X mutation, proved to be simple and convenient. Although any base change in the CpG of codon 329 would eliminate the TaqI site, the assay is simple and sensitive (that is, not prone to false negatives, normal PCR product is digested completely), and can be reinforced where needed by BsrI assay, SSCP, or sequencing. We have since extended this approach'7 to a PCR system applicable to any CpG site, in which both PCR primers are sited directly adjacent to the CpG dinucleotide of interest and both primers have a 3' T base (forcing if necessary), so that in the normal state a TaqI site is induced. If the CpG site contains a mutation, the TaqI site is lost. This system (CpG-PCR) creates a final common pathway for the analysis for any CpG mutation and further details of a range of CpG-PCR induced restriction site assays examined for R329X, as well as several other mutations, have been presented. '7 The observation that R329X is in complete linkage disequilibrium with allele 259nt of D19S394 in the probands from the south of England has several important implications. Firstly, within a collection of probands from a particular region, it may be possible to use DI 9S394 to identify subset(s) with a common mutation. Whether formal statistical significance is attained will depend on the number of FH probands in the study, the frequency in a control group of the DI 9S394 allele size marking the common mutation, and the frequency of the common mutation in the FH probands. For 100 probands, a mutation at 10% prevalence and marked by a D19S394 allele size with 10% population prevalence, 30 instead of 20 out of 200 alleles will have that allele size. In conclusion, LDLR gene mutation R329X is a significant contributor to the burden of FH in the south of England. Of wider applicability in FH, the use of polymorphic microsatellite Dl 9S394 has been illustrated for linkage disequilibrium studies and family studies. The use of flanking microsatellites in place of intragenic RFLP based haplotyping warrants further development for analysis by linkage disequilibrium and cosegregation of FH mutations both in populations and families. 
